Fluidigm's Q4 Revenues Climb 36 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Reporting as a public company for the first time, Fluidigm today said that its fourth-quarter revenues increased 36 percent while it trimmed its net loss year over year.

The South San Francisco-based microfluidics and sample preparation technologies firm brought in total revenues of $10.4 million for the three months ended Dec. 31, 2010, compared to $7.6 million for the fourth quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions.

Ancestry.com is eyeing an expansion into genomic risk assessments, the Verge reports.